Therefore, novel DNMT1 inhibitors such as azacitidine, decitabine, and guadecitabine, which can make cancer patients sensitive to immune checkpoint blockade therapy, have shown potential antitumor effects in breast cancer cells [114]. This evidence concerns the gene DNMT1 and breast carcinoma.